膀胱腫瘍に対する抗腫瘍剤マイトマイシン C および放射性同位元素 ^<32>P の膀胱内注入療法 : (IV) M.M.C 膀胱内注入に関する臨床的研究 (血中濃度と臨床成績)

概要

論文の詳細を見る
IV. Clinical Studies 1. Plasma levels of MMC following a single intracavitary dose of 80 ml of a 1,000 mg/ml solution averaged 0.0026 and 0.0025 mcg/ml at 30 and 60 minutes after the instillation in patients with vesical carcinomatosis. Meanwhile, reports of plasma levels of the compound in bladder tumor patients as yet are, to our knowledge, non-existent. 2. The results of a clinical trial with a 2.000 mcg/ml solution of MMC of 5, 10 and 20 ml (single dose) in 25 patients were that the indications for the intracavitary chemotherapy were multiple papillomatosis and transitional cellcarcinoma of the bladder with tumors of up to 1 cm in diameter and with in the stage ranging from O toB_1, wherein no significant relations were observed between the grade of neoplasm and the clinical effects. In contrast, the therapy was found to be not significantly beneficial insolitary tumors of more than 2 cm in diameter and of stages beyond B_1 Especially this therapy in squamous cellcarcinoma was in effective.
社団法人日本泌尿器科学会の論文